Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


Adjuvants in influenza vaccines.

Tetsutani K, Ishii KJ.

Vaccine. 2012 Dec 14;30(52):7658-61. doi: 10.1016/j.vaccine.2012.10.007. Epub 2012 Oct 19. Review.


Inactivated and adjuvanted influenza vaccines.

Del Giudice G, Rappuoli R.

Curr Top Microbiol Immunol. 2015;386:151-80. doi: 10.1007/82_2014_406. Review.


MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action.

Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F, Monaci E, Baudner B, Seubert A, De Gregorio E.

J Immunol. 2012 Apr 1;188(7):3088-98. doi: 10.4049/jimmunol.1101764. Epub 2012 Feb 20.


Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H.

Sci Transl Med. 2010 Jan 20;2(15):15ra5. doi: 10.1126/scitranslmed.3000624.


Impact of Adjuvants on the Immunogenicity and Efficacy of Split-Virion H7N9 Vaccine in Ferrets.

Wong SS, Kaplan B, Zanin M, Debeauchamp J, Kercher L, Crumpton JC, Seiler P, Sun Y, Tang L, Krauss S, Webster R, Webby RJ.

J Infect Dis. 2015 Aug 15;212(4):542-51. doi: 10.1093/infdis/jiv099. Epub 2015 Feb 23.


Mechanism of action of licensed vaccine adjuvants.

Tritto E, Mosca F, De Gregorio E.

Vaccine. 2009 May 26;27(25-26):3331-4. doi: 10.1016/j.vaccine.2009.01.084. Epub 2009 Feb 5.


The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination.

Vono M, Taccone M, Caccin P, Gallotta M, Donvito G, Falzoni S, Palmieri E, Pallaoro M, Rappuoli R, Di Virgilio F, De Gregorio E, Montecucco C, Seubert A.

Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21095-100. doi: 10.1073/pnas.1319784110. Epub 2013 Dec 9.


Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

Garçon N, Vaughn DW, Didierlaurent AM.

Expert Rev Vaccines. 2012 Mar;11(3):349-66. doi: 10.1586/erv.11.192. Review.


Vaccines against pandemic influenza: what can be done before the next pandemic?

Huber VC, McCullers JA.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S113-7. doi: 10.1097/INF.0b013e318168b749.


Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.

Vaccine. 2008 Jul 4;26(29-30):3640-6. doi: 10.1016/j.vaccine.2008.04.071. Epub 2008 May 15.


The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.

Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, De Gregorio E, O'Hagan DT, Baudner B, Seubert A.

Vaccine. 2013 Jul 18;31(33):3363-9. doi: 10.1016/j.vaccine.2013.05.007. Epub 2013 May 16.


Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garçon N, Van Mechelen M.

Vaccine. 2011 Mar 16;29(13):2461-73. doi: 10.1016/j.vaccine.2011.01.011. Epub 2011 Jan 20.


MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates.

Traquina P, Morandi M, Contorni M, Van Nest G.

J Infect Dis. 1996 Dec;174(6):1168-75.


Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59.

Ellebedy AH, Lupfer C, Ghoneim HE, DeBeauchamp J, Kanneganti TD, Webby RJ.

Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2927-32. doi: 10.1073/pnas.1012455108. Epub 2011 Jan 26. Erratum in: Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4429.


The Safety of Adjuvanted Vaccines Revisited: Vaccine-Induced Narcolepsy.

Ahmed SS, Montomoli E, Pasini FL, Steinman L.

Isr Med Assoc J. 2016 Mar-Apr;18(3-4):216-20. Review.


Molecular and cellular signatures of human vaccine adjuvants.

Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, O'Hagan D, Rappuoli R, De Gregorio E.

Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10501-6. doi: 10.1073/pnas.0804699105. Epub 2008 Jul 23.


MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life.

Mastelic Gavillet B, Eberhardt CS, Auderset F, Castellino F, Seubert A, Tregoning JS, Lambert PH, de Gregorio E, Del Giudice G, Siegrist CA.

J Immunol. 2015 May 15;194(10):4836-45. doi: 10.4049/jimmunol.1402071. Epub 2015 Apr 13.


Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88.

Seubert A, Calabro S, Santini L, Galli B, Genovese A, Valentini S, Aprea S, Colaprico A, D'Oro U, Giuliani MM, Pallaoro M, Pizza M, O'Hagan DT, Wack A, Rappuoli R, De Gregorio E.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11169-74. doi: 10.1073/pnas.1107941108. Epub 2011 Jun 20.


MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice.

Higgins DA, Carlson JR, Van Nest G.

Vaccine. 1996 Apr;14(6):478-84.


Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.

Walker WT, Faust SN.

Expert Rev Vaccines. 2010 Dec;9(12):1385-98. doi: 10.1586/erv.10.141. Review.

Items per page

Supplemental Content

Write to the Help Desk